Income Taxes (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Jan. 01, 2023 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Income Taxes [Line Items] | |||
| Valuation allowance | $ 101,613 | $ 90,565 | |
| Unused net operating losses | 327,800 | ||
| Net operating losses | 104,800 | ||
| Indefinite life | 84,600 | ||
| Net operating loss percentage | 80.00% | ||
| Federal research and development tax credits | 20,664 | $ 18,684 | |
| Research and development costs | 28,000 | ||
| Accumulated gross amount | 87,900 | ||
| Federal income tax [Member] | |||
| Income Taxes [Line Items] | |||
| Unused net operating losses | 189,300 | ||
| Net operating losses due to expire in 2026 [Member] | |||
| Income Taxes [Line Items] | |||
| Net operating losses | 3,900 | ||
| Net operating losses expire in 2034 - 2037 [Member] | |||
| Income Taxes [Line Items] | |||
| Net operating losses | 15,000 | ||
| Tax Year 2033 [Member] | |||
| Income Taxes [Line Items] | |||
| Federal research and development tax credits | 6,700 | ||
| Tax Year 2037 [Member] | Orphan Drug Credits [Member] | |||
| Income Taxes [Line Items] | |||
| Federal research and development tax credits | $ 16,500 |
| X | ||||||||||
- Definition Accumulated gross amount. No definition available.
|
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|